![]() ![]() ![]() SP–304 works by activating a unique receptor on intestinal cells. SP–304 (previously referred to as Guanilib) is an analog (synthetic molecule) of uroguanylin, a natural gastro–intestinal hormone produced in the gut that is a key regulator of intestinal function. More detailed information concerning the financing and related transactions can be found in Form 8–K reports filed with the Securities and Exchange Commission by Callisto and Pawfect on July 18, 2008. We believe Callisto investors and the investors in the new Synergy Pharmaceuticals are best served through this transaction. It is our hope that the separation of Synergy ´s gastrointestinal drug development from Callisto ´s cancer drug development will allow the market to value SP–304 appropriately which the market was not able to do while SP–304 remained completely under Callisto ´s capital structure and depressed market price. Jacob, Callisto CEO and Synergy President and Acting CEO commented, "Raising critically needed capital to fund the continuing development of SP–304 and retaining a 68% interest in the drug ´s future given current market conditions is very encouraging. Jacob will continue to serve as CEO of Callisto. Jacob was appointed President and Acting CEO of Pawfect pending Pawfect recruiting an independent CEO. were appointed to constitute the Pawfect board of directors and, among other officer appointments, Gary S. Cerrone, Callisto Chairman, John Brancaccio, a Callisto director, Chris McGuigan, Ph.D., and Thomas H. " As a result of the financing, exchange of shares, cancellation of 1,981,503.650 of 2,000,000 outstanding shares of Pawfect common stock held by a principal stockholder and Pawfect effecting a 75.69060773 for one forward stock split approved by Pawfect ´s board and principal stockholder expected to be effective within 10 days, Synergy became a wholly owned subsidiary of Pawfect and Callisto retains an approximately 68% interest in Synergy and its GC–C receptor agonist platform. Pawfect Foods has filed an amendment to its articles of incorporation to, among other things, change its corporate name to "Synergy Pharmaceuticals, Inc. Simultaneously with the closing of the placement, Callisto and certain recipients of Synergy restricted stock awards exchanged all of the outstanding stock of Synergy for approximately 70% of the common stock of Pawfect Foods, Inc., a Florida corporation (PWFF.OB). The proceeds of the private placement will be used to fund the development of SP–304, its guanylate cyclase C (GC–C) receptor agonist, for chronic constipation (CC) and constipation–predominant irritable bowel syndrome (IBS–C). (Pink Sheets: CLSP FWB: CA4), announced today that its Synergy Pharmaceuticals, Inc. BONDERMA Is A Dedicated Division Of Synergy Pharmaceuticals To Derma Ranges.Callisto Pharmaceuticals, Inc. We Make Sure That Most Of Our Products Are Produced Under Strict Quality Measures To Ensure Best Results. With A Slogan Of “ Care Commitment Excellence”, We Always Strive To Ensure The Best Quality Products, Best Quality Service And Best Quality In Planning For The Success Of Our Customers And Associates. We Have Expanded Our Product Range To Different Divisions Like Dermatology, Diabetic, Cardiac, Gynecology, Infertility, Dentistry,Ophthalmology, Pediatrics,Neurology, Gastro Enterology, Orthopedics And General Products. Synergy Pharmaceuticals Has A Philosophy Of “Innovating For Excellence”. In Short Span Of Few Years Expanded To Karnataka, Tamilnadu, Kerala, Telangana, Maharashtra, Odisha, West Bengal, Jharkhand, Uttar Pradesh, Bihar And Madhya Pradesh. SSV SATYANARAYANA Who Possesses Vast Experience In Pharmaceutical Marketing In Esteemed Organizations Like Torrent, Sarabhai And GSK Etc. THE SYNERGY PHARMACEUTICALS Came Into Inception In July,2007 In The Guidance Of Mr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |